Early initiation of chemotherapy was not associated with improved survival in patients with early-stage ovarian cancer, a recent study found. This analysis of NRG oncology/gynecologic oncology group trials included 497 stage I-III epithelial ovarian cancer patients and sought to determine the association between timing of adjuvant therapy initiation and survival. Researchers found:
- Median time between surgery and initiation of adjuvant therapy was 23 days; time interval from surgery to initiation of adjuvant therapy was categorized into 3 groups: <2 weeks, 2 to 4 weeks, and >4 weeks.
- Corresponding 5-year recurrence-free survival rates were 72.8%, 73.9%, and 79.5%, respectively.
- 5-year overall survival rates were 79.4%, 81.9%, and 82.8%, respectively.
- Hazard ratio for recurrence-free survival was 0.90 for 2 to 4 weeks and 0.72 for >4 weeks.
Chan JK, Java JJ, Fuh K, et al. The association between timing of initiation of adjuvant therapy and the survival of early state ovarian cancer patients – An analysis of NRG oncology/gynecologic oncology group trials. [Published online ahead of print October 19, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.09.015.
This Week's Must Reads
Must Reads in Gynecologic Cancer
Maternal Factors in Cervical Cancer Prevention, Womens Health Issues; ePub 2019 Jan 10; Charlton, et al
Combined Gynecologic Ca & Pelvic Floor Dysfunction Surgery, Female Pelvic Med Reconstr Surg; ePub 2018 Oct 22; McConnell, et al